Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 188

Results For "NAL"

7130 News Found

ACL Digital acquires US-based CRO Symbiance to expand clinical research capabilities
Digitisation | October 01, 2025

ACL Digital acquires US-based CRO Symbiance to expand clinical research capabilities

The acquisition positions ACL Digital as an end-to-end provider of global clinical research and data CRO solutions


Pfizer agrees to slash prescription drug prices for Americans
News | October 01, 2025

Pfizer agrees to slash prescription drug prices for Americans

Pfizer will participate in TrumpRx.gov, a direct-to-patient purchasing platform offering discount up to 85%


DPIIT and Thermo Fisher Scientific launch BioVerse challenge to fast-track India’s biotech future
Startup | October 01, 2025

DPIIT and Thermo Fisher Scientific launch BioVerse challenge to fast-track India’s biotech future

India currently hosts more than 10,075 biotech startups


AbbVie seeks FDA approval for Pivekimab Sunirine to treat rare, aggressive blood cancer
Drug Approval | October 01, 2025

AbbVie seeks FDA approval for Pivekimab Sunirine to treat rare, aggressive blood cancer

BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma


Wockhardt submits drug application to FDA for Zidebactam-Cefepime for treatment of serious Gram-negative infections
Drug Approval | October 01, 2025

Wockhardt submits drug application to FDA for Zidebactam-Cefepime for treatment of serious Gram-negative infections

This milestone marks the first-ever NDA submission to the U.S. FDA for a drug, fully discovered and developed by an Indian pharmaceutical company


GSK names Luke Miels as next CEO
People | September 30, 2025

GSK names Luke Miels as next CEO

Miels will formally assume the role on January 1, 2026


BMS launches BMS patient connect, expands direct-to-patient access with Sotyktu
News | September 30, 2025

BMS launches BMS patient connect, expands direct-to-patient access with Sotyktu

Eliquis (apixaban) available at more than 40 per cent discount; Sotyktu to be offered at more than 80 per cent discount to current list price


Leqembi wins NMPA nod for once-monthly IV dosing in early Alzheimer’s patients
News | September 30, 2025

Leqembi wins NMPA nod for once-monthly IV dosing in early Alzheimer’s patients

LEQEMBI was initially approved in China in January 2024 for the treatment of Alzheimer’s disease in patients with mild cognitive impairment